+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Healthcare Licensing - Global Trends: By Industry (Biotech) Mid-Year Review

  • ID: 4604804
  • Report
  • July 2018
  • Region: Global
  • 88 pages
  • FinGlobe, Inc
1 of 2
This mid-year review report provides comprehensive analysis on all such licensing deals and negotiations that took place between global biotech companies during January 1, 2018 to June 30, 2018, categorized and summarized by various important aspects such as key countries, across key regions, market capitalization groups, medicine groups, licensing payment arrangements, worldwide vs domestic licensing, and R&D vs commercialization licensing. Such detailed analysis helps to understand the licensing trends and directions during this time period in the global biotech sector.

Key Features:
  • 6 months’ licensing transactions for global biotech sector analyzed at one place
  • Small, medium and big multinational/non-multinational companies covered
  • Curated categorizations of licensing details
  • 8+ variables reflecting different forms of transactions done
  • Licensing trends and directions summarized
The Report is useful to:
  • Global biotech companies planning to introduce products in other countries
  • Companies active in R&D and seeking new market base
  • Healthcare company executives negotiating licensing deals in the global biotech sector
  • Investors analyzing varied kinds of transaction options for licensing deals in the global biotech sector
Key analysis provided: January-June 2018
  • Total number of licensing deals signed in the global biotech sector
  • Total number of companies/institutes involved in the licensing deals for global biotech sector
  • Most licensing deals signed by which country’s biotech companies
  • Most licensing deals signed by which market capitalization group’s biotech companies
  • Most licensing deals signed by which medicine groups for global biotech sector
  • Licensing payment arrangements most followed in the licensing deals for global biotech sector
  • Number of domestic and worldwide licensing in global biotech sector
  • Number of R&D and commercialization licensing in global biotech sector
Note: Product cover images may vary from those shown
2 of 2
Introduction

Research Design
Chapter 1: Analysis of healthcare inventions licensed in global biotech sector during last six months
1.1 Countries with most licensing deals
1.2 Market capitalization groups with most licensing deals
1.3 Medicine groups most active in licensing deals
1.4 Licensing payment arrangements most followed
1.5 Worldwide licensing vs domestic licensing
1.6 R&D licensing vs commercialization licensing
Chapter 2: Analysis of licensing deals in global biotech sector by marketcap groups during last six months
2.1 Licensing deals for each of the marketcap group for each of the country
2.2 Licensing deals for each of the marketcap group across each of the regions
2.3 Licensing deals for each of the marketcap group for each of the medicine group
Chapter 3: Analysis of licensing deals in global biotech sector by medicine groups during last six months
3.1 Licensing deals for each of the medicine group for each of the country
3.2 Licensing deals for each of the medicine group across each of the regions
3.3 Licensing deals for each of the medicine group for each of the marketcap group
Chapter 4: Analysis of licensing payment arrangements followed in global biotech sector during last six months
4.1 Licensing payment arrangements most followed for each of the country
4.2 Licensing payment arrangements most followed across each of the regions
4.3 Licensing payment arrangements most followed for each of the marketcap group
4.4 Licensing payment arrangements most followed for each of the medicine group
Chapter 5: Analysis of worldwide licensing vs. domestic licensing in global biotech sector during last six months
5.1 Worldwide licensing vs domestic licensing for each of the country
5.2 Worldwide licensing vs domestic licensing across each of the regions
5.3 Worldwide licensing vs domestic licensing for each of the marketcap group
5.4 Worldwide licensing vs domestic licensing for each of the medicine group
Chapter 6: Analysis of R&D licensing vs commercialization licensing in global biotech sector during last six months
6.1 R&D licensing vs commercialization licensing for each of the country
6.2 R&D licensing vs commercialization licensing across each of the regions
6.3 R&D licensing vs commercialization licensing for each of the marketcap group
6.4 R&D licensing vs commercialization licensing for each of the medicine group
Chapter 7: Summary and conclusions
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll